VCCircle | In Conversation With Industry Leaders
Join us : Twitter Facebook Linkedin Youtube

Search form

In Conversation

CDC aims to have significant LP interest in PE funds it backs: Murugappan

There are too many Indian PE funds without enough track record, he says.

Shruti Ambavat
Budget 2014: Show tight control over fiscal situation, populism, says Chanda Kochhar

Budget would need to provide clarity about the prospective nature of taxation, she says.

PTI
For us, M&As are about calibrated aggression: Ramesh Swaminathan, CFO of Lupin

The finance head of the drugmaker says inorganic growth in the past now contributes a quarter of revenue.

Jasleen Kaur Batra
Cipla New Ventures’ head Chandru Chawla on investment strategy, attractive segments & more

The venture investment arm of Cipla has backed US-based Chase Pharma, Manipal Group-promoted Stempeutics Research besides two biotech companies.

Lohit Jagwani
Licensing income can bring upsides to our target of $1B revenue by 2018: Kiran Mazumdar-Shaw of Biocon

The company expects its small molecule API and ANDA business to be lead revenue generator followed by research services and branded formulations.

Lohit Jagwani
Our customer base is different from existing banks; main challenge deposit mobilisation, reskilling staff: Bandhan chief Chandra Shekhar Ghosh

The MFI plans to appoint a consultancy firm to help it set up banking operations.

Anuradha Verma
Yatra will break even in less than a year: CEO Dhruv Shringi

The online travel agency, which has raised $120 million in funding to date, derives one-fifth of its traffic from mobile.

Anand Rai
We plan to expand in a hub and spoke model: Gaurav Malhotra, MD & CEO of Bourn Hall India

TVM Capital has committed $100 million investment in the UK-based parent of the IVF treatment chain.

Lohit Jagwani
Products add a great recall value to the brand: S Subramanian, CEO, Marico Kaya

The head of the beauty services and products company says going forward the products unit will generate 25 per cent of revenue against 20 per cent now.

Diksha Dutta
India Infoline will help in deal sourcing, fundraising and exit management: India Alternatives’ chief Shivani Bhasin Sachdeva

The founder and CEO of the PE firm says the deal with India Infoline took a long time to seal, which affected new investments.

Shruti Ambavat
Our investment in Flipkart is now worth a little less than 300 times: Subrata Mitra, partner, Accel Partners

Mitra says Flipkart is more like Amazon while Myntra is like ASOS.

Shrija Agrawal
Indian infrastructure needs a 15-year investment horizon: MK Sinha, managing partner and CEO of IDFC Alternatives

Sinha claims IDFC Alternatives has been the only fund that has consistently distributed capital right from year one.

Shrija Agrawal
We are looking to raise $500M in two years globally: Helmut M Schühsler, chairman, TVM Capital

The global network of PE firms has recently added India to its investment strategy for emerging markets.

Lohit Jagwani
Indian GPs have a perception problem, they send contradictory messages to global LPs: Markus Ableitinger of Capital Dynamics

The MD and co-head of Investment Management Asia at the private asset management firm says 80% of local PE fund managers are dead or inactive.

Madhav A Chanchani
We are aiming at annual revenues of Rs 5,000Cr in 3 years: RK Arora of Supertech

The chief of the north-based realtor says land prices will increase with the new land acquisition policy which will affect supply of affordable housing.

Swet Sarika
Private cos not the best investment strategy for PE; public investing is very interesting in India: Sumir Chadha of WestBridge Capital

A flexible investment strategy is a good way to invest in India if you have a team of GPs that has the track record and will to do it, according to Chadha.

Madhav A Chanchani
We are looking at a turnover of $1B by 2017: Azad Moopen, chairman of Aster DM Healthcare

The group, which secured $100 million from Olympus Capital in 2011, is looking to go for an IPO either in London or Mumbai.

Lohit Jagwani
We are closely looking at companies in food, media and tiles business in India: Creador’s Brahmal Vasudevan

Vasudevan says he prefers investing in Southeast Asia as valuations are less stretched in the region.

Swet Sarika
Indian clinical trial sector would see significant consolidation: DA Prasanna, chairman of Ecron Acunova

The firm, which has the backing of Manipal Group and healthcare PE firm OrbiMed, has been aggressively looking to expand overseas.

Lohit Jagwani

Pages

Upcoming Events

chinetwork

Copyright © 2014 VCCircle.com.
A property of Mosaic Media Ventures Pvt Ltd.